HeartBeam (NasdaqCM:BEAT) FY Conference Summary Company Overview - **Company**: HeartBeam - **Industry**: Medical Devices, specifically in cardiac monitoring technology - **Key Technology**: Development of a cable-free synthesized 12-lead ECG platform for at-home use, aimed at improving heart attack detection and reducing pre-hospital delays in care [2][4][31] Core Points and Arguments Company Background - **Founder**: Branislav Vajdic, co-inventor of flash memory at Intel, inspired to create HeartBeam after a personal family tragedy related to heart disease [2][3] - **Problem Addressed**: Heart attacks are the leading cause of death, with significant delays in patient response time before reaching hospitals [3][4] Product and Technology - **Device Functionality**: The HeartBeam device allows patients to perform a 12-lead ECG at home, providing real-time clinical-grade insights [4][6] - **FDA Clearances**: Received two FDA clearances, enabling the launch of the device and its associated algorithms [11][31] - **Market Potential**: Targeting an initial market of 5 million patients in the US, with potential expansion to over 50 million patients at risk of heart disease [10][11] Market Strategy - **Initial Target Market**: Focus on concierge and preventive cardiology practices, with a subscription model priced between $500-$1,000 per year per patient [12][14] - **Patient Engagement**: Plans to enhance patient retention through wellness AI algorithms and community features [39][40] - **Sales Strategy**: Aiming for a capital-efficient model without a large sales force, leveraging partnerships with practices to drive patient adoption [17][33] Financial Overview - **Recent Financial Performance**: Reported a net loss of $21 million for FY 2025, with a focus on maintaining capital efficiency [28][29] - **Projected Cash Outflows**: Expected operating cash outflows of $17-$19 million for 2026, with plans to achieve cash flow break-even at around 30,000 patients [30][31] Future Initiatives - **Heart Attack Detection**: Ongoing clinical studies to validate the device's effectiveness in detecting heart attacks, with plans for indication expansion [19][33] - **12-Lead Patch Development**: Working on a patch that converts symptoms into a 12-lead ECG, targeting the $2 billion ambulatory cardiac monitoring market [20][21] - **AI Integration**: Collaborating with Mount Sinai to develop AI algorithms for predictive screening and heart attack detection [24][25] Additional Important Insights - **Market Research Findings**: 80% of high-net-worth individuals expressed interest in purchasing the device, indicating strong demand [12] - **Competitive Landscape**: The device's 12-lead capability differentiates it from existing single-lead devices, potentially capturing a significant market share [42][44] - **Partnerships**: The collaboration with ClearCardio and Mount Sinai is seen as a strategic move to enhance product offerings and market reach [17][25] This summary encapsulates the key points from the HeartBeam FY Conference, highlighting the company's innovative approach to cardiac monitoring and its strategic plans for market entry and growth.

Heartbeam (NasdaqCM:BEAT) Q4 2025 Earnings call March 12, 2026 04:30 PM ET Company ParticipantsBryan Humbarger - CCORobert Eno - Founder and Executive ChairmanTimothy Cruickshank - CFONone - Company RepresentativeConference Call ParticipantsBill Sutherland - Equity Research AnalystKyle Bauser - Equity Research AnalystLeo Carpio - Equity Research AnalystNone - AnalystOperatorGreetings, and welcome to the HeartBeam fourth quarter 2025 financial results conference call. At this time, all participants are in a ...

Heartbeam (NasdaqCM:BEAT) Q4 2025 Earnings call March 12, 2026 04:30 PM ET Company ParticipantsBryan Humbarger - CCORobert Eno - Founder and Executive ChairmanTimothy Cruickshank - CFONone - Company RepresentativeConference Call ParticipantsBill Sutherland - Equity Research AnalystKyle Bauser - Equity Research AnalystLeo Carpio - Equity Research AnalystNone - AnalystOperatorGreetings, and welcome to the HeartBeam Q4 2025 financial results conference call. At this time, all participants are in a listen-only ...

Financial Data and Key Metrics Changes - For the full year 2025, the net loss was $21 million or $0.62 per share, while the fourth quarter net loss was $5.3 million or $0.15 per share, aligning with expectations [28] - Net cash used in operating activities was less than $14 million for the full year and just $2.9 million for the fourth quarter, representing a 3% decrease year-over-year and a 30% decrease compared to the same quarter last year [28][29] - Cash and cash equivalents totaled $4.4 million at December 31, 2025, with access to capital markets remaining strong [29] Business Line Data and Key Metrics Changes - HeartBeam's core technology includes a portable cable-free ECG that synthesizes a 12-lead ECG, with FDA 510(k) clearance achieved for arrhythmia assessment [5][6] - The company is launching a second form factor, an on-demand 12-lead extended wear patch, which is expected to disrupt the $2 billion ambulatory cardiac monitoring market [8][20] - The initial commercial launch is focused on concierge and preventive cardiology practices, targeting a price per patient of $500-$1,000 per year [11][12] Market Data and Key Metrics Changes - The target market includes approximately 1.5 million Americans currently paying for concierge medicine, with a focus on high-net-worth individuals who show a strong willingness to adopt advanced health technology [11][12] - The company aims to capture a small portion of the concierge market initially, with plans to expand into larger patient segments, including direct primary care practices and telehealth networks [12][13] Company Strategy and Development Direction - HeartBeam's strategy involves a staged approach to commercialization, starting with a limited launch in concierge cardiology and executive health [13][16] - The company plans to validate its model in a concentrated market before scaling, with a focus on deep adoption within initial practices [12][16] - The collaboration with Mount Sinai aims to enhance AI capabilities and bring advanced algorithms to the HeartBeam device [25][98] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand for the HeartBeam system, highlighting the strong interest from both patients and physicians [10][11] - The company anticipates significant advancements in 2026, with ongoing studies and product launches expected to drive growth [32][34] - The management emphasized maintaining financial discipline while advancing key milestones and developing the R&D pipeline [28][29] Other Important Information - The HeartBeam 12-lead patch is expected to provide better diagnostic capabilities and integrate into existing workflows, leveraging existing reimbursement [20][21] - The company has completed a working prototype of the patch and is conducting clinical studies to validate its effectiveness [23][26] Q&A Session Summary Question: Can you talk about the timeline for the ALIGN pilot study and the patch initiatives? - Management indicated that the ALIGN-ACS pilot study is expected to enroll quickly due to its design, with completion anticipated by the end of Q3 2026 [36][39] Question: What does the account pipeline look like for the commercialization strategy? - The focus is on a limited number of anchor accounts initially, with plans to validate the premium value proposition before scaling [41][43] Question: How should we think about R&D expenses trending in the upcoming quarters? - R&D expenses are expected to step up slightly in the first half of the year due to clinical trials, then return to baseline levels [49][51] Question: Can you provide details on the Mount Sinai relationship and potential for similar alliances? - The relationship with Mount Sinai was built on mutual respect and shared goals in advancing AI algorithms for ECG data, with openness to future partnerships [96][98]

Total Heart Intelligence… Wherever You Are FOURTH QUARTER 2025 FINANCIAL RESULTS CONFERENCE CALL MARCH 12, 2026 NASDAQ: BEAT Disclaimer The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its business, financial condition and results of operations. Also, these forward-looking statements represent the Company's estimates and assumptions only as of the date of this presentation. The Comp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period over from ___________ to ___________ Commission File Number: 001-41060 HEARTBEAM, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4881450 State or Other Ju ...

Total Heart Intelligence… Wherever You Are ADVANCED CARDIAC INTELLIGENCE PLATFORM | 25 PATENTS | FDA CLEARED INVESTOR PRESENTATION March 12, 2026 Investor Presentation 2026 NASDAQ : BEAT Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to the Company's future results of operations and financial position, planned products and services, business strategy and plans and objectives of ...

Heartbeam shares are powering higher. What’s driving BEAT stock higher?HeartBeam And Mount Sinai Partner On AI-ECG DevelopmentThe collaboration will combine HeartBeam's patented ECG platform with Mount Sinai's artificial intelligence and clinical expertise to develop and validate advanced AI-ECG algorithms.HeartBeam's platform captures the heart's electrical activity from three non-coplanar dimensions and is capable of collecting synthesized 12-lead ECG data from patients remotely over time.The companies sa ...

Core Insights - HeartBeam (BEAT) has received FDA 510(k) clearance for its innovative cable-free synthesized 12-lead ECG technology, marking a significant milestone in cardiac diagnostics modernization [1][7][9] - The company plans to launch its product in early 2026 through concierge and preventive cardiology practices that have shown strong interest [2][10] Regulatory Approval - The FDA clearance followed a successful appeal that overturned a previous Not Substantially Equivalent (NSE) decision, validating HeartBeam's clinical evidence and enhancing its credibility for commercialization [9] - This approval allows HeartBeam to pursue additional regulatory pathways, including heart-attack detection, which represents a substantial market opportunity [9] Market Position and Growth Potential - The clearance positions HeartBeam for long-term growth by legitimizing its core technology and enabling entry into large reimbursable markets such as extended-wear monitoring [4] - HeartBeam currently has a market capitalization of $27.7 million, and its shares have decreased by 32.8% year-to-date, contrasting with the industry's 8.7% growth [3][4] Product Features and Benefits - HeartBeam's device captures the heart's electrical activity in three non-coplanar dimensions, providing a clinical-grade 12-lead ECG that can be recorded at the moment symptoms occur, unlike traditional wearables [6][8] - This technology offers physicians improved diagnostic clarity for arrhythmias, potentially speeding up intervention [8] Strategic Initiatives - HeartBeam is preparing a limited U.S. launch in early 2026, allowing for real-world performance validation and refinement of its commercial model [10] - The company is also developing a 12-lead extended-wear patch prototype and AI-based screening tools using its longitudinal ECG dataset, indicating a well-sequenced growth strategy [11]

Core Insights - HeartBeam, Inc. has received FDA 510(k) clearance for its 12-lead ECG synthesis software, enabling at-home assessment of arrhythmias [1][2] - The stock price has surged by 75.73% to $1.42 following the announcement [7] Group 1: FDA Clearance and Technology - The FDA clearance follows HeartBeam's successful appeal against a previous Not Substantially Equivalent determination [2] - HeartBeam's technology captures heart electrical signals in three dimensions, providing a comprehensive 12-lead ECG representation [2] Group 2: Growth Initiatives - The company plans a limited launch in early 2026 targeting select concierge and preventive cardiology practices to validate real-world performance [3][7] - HeartBeam aims to pursue an additional indication for heart attack detection, potentially reaching tens of millions of U.S. patients [4] Group 3: Product Development - The company is developing an extended-wear 12-lead ECG patch, currently at the working-prototype stage, targeting a multi-billion-dollar reimbursable market [5] - HeartBeam intends to leverage longitudinal data from its 3D ECG technology for AI-driven screening and predictive tools [6]